HS

Henry Schein, Inc.

HSICHealthcareNASDAQ

Medical Distribution

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$13.18B
+4.0% YoY
Net Income
$398.0M
+2.1% YoY
EBITDA
$964.0M
+5.7% YoY
Free Cash Flow
$290.1M

Scan Results

Daily timeframe
6 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 11 MACD Negative CrossoverHistogram -0.1468, negative momentum
Jul 10 MACD Negative CrossoverHistogram -0.0645, negative momentum
About Henry Schein, Inc.

Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. The $9.93B market capitalization puts HSIC squarely in mid-cap range for its industry. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments.

Key stats
Market Cap$9.93B
P/E (TTM)26.25
Fwd P/E14.75
EPS$3.32
Beta0.81
52W Change+25.7%
ROE8.8%
Analysis

Henry Schein, Inc. carries $3.75B in total debt against $138.0M in cash reserves — debt is roughly 27.2x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $290.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 8.8%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.4% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $12.65B (2022) to $13.18B (2025).

Henry Schein, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing HSIC.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms